Cargando…

An oncolytic virus as a promising candidate for the treatment of radioresistant oral squamous cell carcinoma

We evaluated the usefulness of an oncolytic virus (Suratadenoturev; OBP-301) against radioresistant oral squamous cell carcinoma. We confirmed the expression of human telomerase reverse transcriptase and the coxsackievirus and adenovirus receptor in cell lines. Also, we examined the potential presen...

Descripción completa

Detalles Bibliográficos
Autores principales: Gohara, Shunsuke, Shinohara, Kosuke, Yoshida, Ryoji, Kariya, Ryusho, Tazawa, Hiroshi, Hashimoto, Masashi, Inoue, Junki, Kubo, Ryuta, Nakashima, Hikaru, Arita, Hidetaka, Kawaguchi, Sho, Yamana, Keisuke, Nagao, Yuka, Iwamoto, Asuka, Sakata, Junki, Matsuoka, Yuichiro, Takeshita, Hisashi, Hirayama, Masatoshi, Kawahara, Kenta, Nagata, Masashi, Hirosue, Akiyuki, Kuwahara, Yoshikazu, Fukumoto, Manabu, Okada, Seiji, Urata, Yasuo, Fujiwara, Toshiyoshi, Nakayama, Hideki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9619351/
https://www.ncbi.nlm.nih.gov/pubmed/36381653
http://dx.doi.org/10.1016/j.omto.2022.10.001
_version_ 1784821256164474880
author Gohara, Shunsuke
Shinohara, Kosuke
Yoshida, Ryoji
Kariya, Ryusho
Tazawa, Hiroshi
Hashimoto, Masashi
Inoue, Junki
Kubo, Ryuta
Nakashima, Hikaru
Arita, Hidetaka
Kawaguchi, Sho
Yamana, Keisuke
Nagao, Yuka
Iwamoto, Asuka
Sakata, Junki
Matsuoka, Yuichiro
Takeshita, Hisashi
Hirayama, Masatoshi
Kawahara, Kenta
Nagata, Masashi
Hirosue, Akiyuki
Kuwahara, Yoshikazu
Fukumoto, Manabu
Okada, Seiji
Urata, Yasuo
Fujiwara, Toshiyoshi
Nakayama, Hideki
author_facet Gohara, Shunsuke
Shinohara, Kosuke
Yoshida, Ryoji
Kariya, Ryusho
Tazawa, Hiroshi
Hashimoto, Masashi
Inoue, Junki
Kubo, Ryuta
Nakashima, Hikaru
Arita, Hidetaka
Kawaguchi, Sho
Yamana, Keisuke
Nagao, Yuka
Iwamoto, Asuka
Sakata, Junki
Matsuoka, Yuichiro
Takeshita, Hisashi
Hirayama, Masatoshi
Kawahara, Kenta
Nagata, Masashi
Hirosue, Akiyuki
Kuwahara, Yoshikazu
Fukumoto, Manabu
Okada, Seiji
Urata, Yasuo
Fujiwara, Toshiyoshi
Nakayama, Hideki
author_sort Gohara, Shunsuke
collection PubMed
description We evaluated the usefulness of an oncolytic virus (Suratadenoturev; OBP-301) against radioresistant oral squamous cell carcinoma. We confirmed the expression of human telomerase reverse transcriptase and the coxsackievirus and adenovirus receptor in cell lines. Also, we examined the potential presence in a patient who has received existing therapy that is amenable to treatment with OBP-301. We evaluated: (1) the antitumor effects of OBP-301 alone and in combination with radiotherapy on radioresistant cell lines, (2) the molecular mechanism underlying the radiosensitizing effect and cell death increased by the combination therapy, and (3) the antitumor effect of the combination therapy in vivo using xenograft models (a radioresistant cell line-derived xenograft in mouse and a patient-derived xenograft). Human telomerase reverse transcriptase and the coxsackievirus and adenovirus receptor were expressed in all cell lines. OBP-301 decreased the proliferative activity of these cell lines in a concentration-dependent manner, and significantly enhanced the antitumor effect of irradiation. Phosphorylated STAT3 and its downstream molecules, which correlated with apoptosis and autophagy, showed significant changes in expression after treatment with OBP-301. The combination therapy exerted a significant antitumor effect versus radiotherapy alone in both xenograft models. Combination of OBP-301 with radiotherapy exerts a synergistic effect and may represent a promising treatment for radioresistant oral squamous cell carcinoma.
format Online
Article
Text
id pubmed-9619351
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Society of Gene & Cell Therapy
record_format MEDLINE/PubMed
spelling pubmed-96193512022-11-14 An oncolytic virus as a promising candidate for the treatment of radioresistant oral squamous cell carcinoma Gohara, Shunsuke Shinohara, Kosuke Yoshida, Ryoji Kariya, Ryusho Tazawa, Hiroshi Hashimoto, Masashi Inoue, Junki Kubo, Ryuta Nakashima, Hikaru Arita, Hidetaka Kawaguchi, Sho Yamana, Keisuke Nagao, Yuka Iwamoto, Asuka Sakata, Junki Matsuoka, Yuichiro Takeshita, Hisashi Hirayama, Masatoshi Kawahara, Kenta Nagata, Masashi Hirosue, Akiyuki Kuwahara, Yoshikazu Fukumoto, Manabu Okada, Seiji Urata, Yasuo Fujiwara, Toshiyoshi Nakayama, Hideki Mol Ther Oncolytics Original Article We evaluated the usefulness of an oncolytic virus (Suratadenoturev; OBP-301) against radioresistant oral squamous cell carcinoma. We confirmed the expression of human telomerase reverse transcriptase and the coxsackievirus and adenovirus receptor in cell lines. Also, we examined the potential presence in a patient who has received existing therapy that is amenable to treatment with OBP-301. We evaluated: (1) the antitumor effects of OBP-301 alone and in combination with radiotherapy on radioresistant cell lines, (2) the molecular mechanism underlying the radiosensitizing effect and cell death increased by the combination therapy, and (3) the antitumor effect of the combination therapy in vivo using xenograft models (a radioresistant cell line-derived xenograft in mouse and a patient-derived xenograft). Human telomerase reverse transcriptase and the coxsackievirus and adenovirus receptor were expressed in all cell lines. OBP-301 decreased the proliferative activity of these cell lines in a concentration-dependent manner, and significantly enhanced the antitumor effect of irradiation. Phosphorylated STAT3 and its downstream molecules, which correlated with apoptosis and autophagy, showed significant changes in expression after treatment with OBP-301. The combination therapy exerted a significant antitumor effect versus radiotherapy alone in both xenograft models. Combination of OBP-301 with radiotherapy exerts a synergistic effect and may represent a promising treatment for radioresistant oral squamous cell carcinoma. American Society of Gene & Cell Therapy 2022-10-08 /pmc/articles/PMC9619351/ /pubmed/36381653 http://dx.doi.org/10.1016/j.omto.2022.10.001 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Original Article
Gohara, Shunsuke
Shinohara, Kosuke
Yoshida, Ryoji
Kariya, Ryusho
Tazawa, Hiroshi
Hashimoto, Masashi
Inoue, Junki
Kubo, Ryuta
Nakashima, Hikaru
Arita, Hidetaka
Kawaguchi, Sho
Yamana, Keisuke
Nagao, Yuka
Iwamoto, Asuka
Sakata, Junki
Matsuoka, Yuichiro
Takeshita, Hisashi
Hirayama, Masatoshi
Kawahara, Kenta
Nagata, Masashi
Hirosue, Akiyuki
Kuwahara, Yoshikazu
Fukumoto, Manabu
Okada, Seiji
Urata, Yasuo
Fujiwara, Toshiyoshi
Nakayama, Hideki
An oncolytic virus as a promising candidate for the treatment of radioresistant oral squamous cell carcinoma
title An oncolytic virus as a promising candidate for the treatment of radioresistant oral squamous cell carcinoma
title_full An oncolytic virus as a promising candidate for the treatment of radioresistant oral squamous cell carcinoma
title_fullStr An oncolytic virus as a promising candidate for the treatment of radioresistant oral squamous cell carcinoma
title_full_unstemmed An oncolytic virus as a promising candidate for the treatment of radioresistant oral squamous cell carcinoma
title_short An oncolytic virus as a promising candidate for the treatment of radioresistant oral squamous cell carcinoma
title_sort oncolytic virus as a promising candidate for the treatment of radioresistant oral squamous cell carcinoma
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9619351/
https://www.ncbi.nlm.nih.gov/pubmed/36381653
http://dx.doi.org/10.1016/j.omto.2022.10.001
work_keys_str_mv AT goharashunsuke anoncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma
AT shinoharakosuke anoncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma
AT yoshidaryoji anoncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma
AT kariyaryusho anoncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma
AT tazawahiroshi anoncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma
AT hashimotomasashi anoncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma
AT inouejunki anoncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma
AT kuboryuta anoncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma
AT nakashimahikaru anoncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma
AT aritahidetaka anoncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma
AT kawaguchisho anoncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma
AT yamanakeisuke anoncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma
AT nagaoyuka anoncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma
AT iwamotoasuka anoncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma
AT sakatajunki anoncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma
AT matsuokayuichiro anoncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma
AT takeshitahisashi anoncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma
AT hirayamamasatoshi anoncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma
AT kawaharakenta anoncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma
AT nagatamasashi anoncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma
AT hirosueakiyuki anoncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma
AT kuwaharayoshikazu anoncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma
AT fukumotomanabu anoncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma
AT okadaseiji anoncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma
AT uratayasuo anoncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma
AT fujiwaratoshiyoshi anoncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma
AT nakayamahideki anoncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma
AT goharashunsuke oncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma
AT shinoharakosuke oncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma
AT yoshidaryoji oncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma
AT kariyaryusho oncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma
AT tazawahiroshi oncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma
AT hashimotomasashi oncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma
AT inouejunki oncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma
AT kuboryuta oncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma
AT nakashimahikaru oncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma
AT aritahidetaka oncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma
AT kawaguchisho oncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma
AT yamanakeisuke oncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma
AT nagaoyuka oncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma
AT iwamotoasuka oncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma
AT sakatajunki oncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma
AT matsuokayuichiro oncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma
AT takeshitahisashi oncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma
AT hirayamamasatoshi oncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma
AT kawaharakenta oncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma
AT nagatamasashi oncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma
AT hirosueakiyuki oncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma
AT kuwaharayoshikazu oncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma
AT fukumotomanabu oncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma
AT okadaseiji oncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma
AT uratayasuo oncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma
AT fujiwaratoshiyoshi oncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma
AT nakayamahideki oncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma